Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Walter Reinisch

Showing results (131-140 of 352) with videos related to

Pageof 36
Sort By:
Inflammatory Bowel Diseases|June 9, 2009
Endoscopy and MR enteroclysis: equivalent tools in predicting clinical recurrence in patients with Crohn's disease after ileocolic resectionStavroula Koilakou, Johannes Sailer, Philipp Peloschek, et al.
The American Journal of Gastroenterology|September 25, 2013
Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantationSieglinde Angelberger, Walter Reinisch, Athanasios Makristathis, et al.
The American Journal of Gastroenterology|January 8, 2026
Clinical Trial Endpoints for Perianal Fistulizing Crohn's DiseaseWalter Reinisch, Raja Atreya, Florian Rieder, et al.
Digestive Diseases and Sciences|April 29, 2023
Comparative Efficacy of Infliximab Versus Tofacitinib for Inducing Remission in Biologic Naive Ulcerative Colitis: A Propensity Matched StudyEmily C L Wong, Shahin Merat, Cristina Monaco, et al.
Journal of Crohn'S & Colitis|September 20, 2024
Outcomes of Patients With Prior Biologic Intolerance Are Better Than Those With Biologic Failure in Clinical Trials of Inflammatory Bowel DiseaseSunil Samnani, Emily C L Wong, Hasan Hamam, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 10, 2021
Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Naïve Crohn's DiseaseNeeraj Narula, Emily C L Wong, Parambir S Dulai, et al.
Journal of Crohn'S & Colitis|February 7, 2019
Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical TrialsStephen Hanauer, William J Sandborn, Jean-Frederic Colombel, et al.
Scandinavian Journal of Gastroenterology|November 4, 2005
A prospective, open-label trial of 6-thioguanine in patients with ulcerative or indeterminate colitisAlexander Teml, Matthias Schwab, Marieluise Harrer, et al.
Journal of Crohn'S & Colitis|April 7, 2012
Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: results from the CARE trialEdouard Louis, Robert Löfberg, Walter Reinisch, et al.
Inflammatory Bowel Diseases|July 8, 2020
Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's DiseaseWalter Reinisch, Krisztina Gecse, Jonas Halfvarson, et al.
Pageof 36

Showing results (131-140 of 352) with videos related to

Sort By:
Pageof 36
Inflammatory Bowel Diseases|June 9, 2009
Endoscopy and MR enteroclysis: equivalent tools in predicting clinical recurrence in patients with Crohn's disease after ileocolic resectionStavroula Koilakou, Johannes Sailer, Philipp Peloschek, et al.
The American Journal of Gastroenterology|September 25, 2013
Temporal bacterial community dynamics vary among ulcerative colitis patients after fecal microbiota transplantationSieglinde Angelberger, Walter Reinisch, Athanasios Makristathis, et al.
The American Journal of Gastroenterology|January 8, 2026
Clinical Trial Endpoints for Perianal Fistulizing Crohn's DiseaseWalter Reinisch, Raja Atreya, Florian Rieder, et al.
Digestive Diseases and Sciences|April 29, 2023
Comparative Efficacy of Infliximab Versus Tofacitinib for Inducing Remission in Biologic Naive Ulcerative Colitis: A Propensity Matched StudyEmily C L Wong, Shahin Merat, Cristina Monaco, et al.
Journal of Crohn'S & Colitis|September 20, 2024
Outcomes of Patients With Prior Biologic Intolerance Are Better Than Those With Biologic Failure in Clinical Trials of Inflammatory Bowel DiseaseSunil Samnani, Emily C L Wong, Hasan Hamam, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 10, 2021
Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Naïve Crohn's DiseaseNeeraj Narula, Emily C L Wong, Parambir S Dulai, et al.
Journal of Crohn'S & Colitis|February 7, 2019
Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical TrialsStephen Hanauer, William J Sandborn, Jean-Frederic Colombel, et al.
Scandinavian Journal of Gastroenterology|November 4, 2005
A prospective, open-label trial of 6-thioguanine in patients with ulcerative or indeterminate colitisAlexander Teml, Matthias Schwab, Marieluise Harrer, et al.
Journal of Crohn'S & Colitis|April 7, 2012
Adalimumab improves patient-reported outcomes and reduces indirect costs in patients with moderate to severe Crohn's disease: results from the CARE trialEdouard Louis, Robert Löfberg, Walter Reinisch, et al.
Inflammatory Bowel Diseases|July 8, 2020
Clinical Practice of Adalimumab and Infliximab Biosimilar Treatment in Adult Patients With Crohn's DiseaseWalter Reinisch, Krisztina Gecse, Jonas Halfvarson, et al.
Pageof 36